Adamas Pharmaceuticals said it has named Alfred Merriweather as its new CFO, reporting to Gregory Went, chairman and CEO. Merriweather succeeds William Dawson who is retiring. Merriweather will oversee the company’s financial and administration organization, including its teams in finance, accounting, Securities and Exchange Commission reporting, treasury, investor relations and human resources.
Merriweather has previously worked for Raindance Technologies, Inc. (acquired by Bio-Rad Laboratories (BIO)), Verinata Health, Inc. (acquired by Illumina (ILMN)), Celera Corporation, Monogram Biosciences, Inc., and Laserscope. He is a graduate of the University of Cambridge.